Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Read about our new masking policy »

Sequencing Antigen-Targeting Antibodies and Cellular Therapies in Adults With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. American journal of hematology Aldoss, I., Shah, B. D., Park, J. H., Muffly, L., Logan, A. C., Brown, P., Stock, W., Jabbour, E. J. 2023

Abstract

The recent approvals of four CD19- or CD22-targeted therapies for B-cell acute lymphoblastic leukemia (B-ALL) have transformed the treatment of relapsed/refractory (r/r) disease. Adults with r/r B-ALL are usually eligible for all options, but there are no studies directly comparing these agents, and the treating physician must decide which to select. Each therapy has notable activity as a single agent but has limitations in particular settings, and the optimal choice varies. These therapies can be complementary and used either sequentially or concomitantly. Here, we review the current landscape of antigen-targeted therapies for r/r B-ALL and discuss considerations for their use. This article is protected by copyright. All rights reserved.

View details for DOI 10.1002/ajh.26853

View details for PubMedID 36691748